UNIGE document Scientific Article
previous document  unige:2086  next document
add to browser collection

Engineered CCR5 superagonist chemokine as adjuvant in anti-tumor DNA vaccination

Dorgham, Karim
Abadie, Valérie
Iga, Mutsunori
Gorochov, Guy
Combadière, Behazine
Published in Vaccine. 2008, vol. 26, no. 26, p. 3252-60
Abstract Chemokine receptors are promising targets for enhancing T-cell immunity and anti-cancer therapy. CCL5 is a potential adjuvant for DNA vaccination. We postulated that CCR5 superagonists could be even more effective. A CCR5 superagonist derived from natural CCL5 by directed in vitro evolution, namely 1P7, is used as a DNA vaccine adjuvant and expressed as fused chemokine-Ig (1P7-Ig). We show that OVA+1P7-Ig DNA co-inoculation induced higher frequencies of OVA-specific CD8 lymphocytes than OVA+CCL5-Ig or controls and gave an even better protection against tumor growth in a CCR5-dependant manner. Our results indicate that CCR5-superagonists may provide potent adjuvants for vaccines.
Keywords Adjuvants, ImmunologicAnimalsCD8-Positive T-Lymphocytes/immunologyCancer Vaccines/immunologyChemokine CCL5/genetics/immunology/pharmacologyFemaleMiceMice, Inbred C57BLOvalbumin/immunologyReceptors, CCR5/agonistsVaccination/methodsVaccines, DNA/immunology
PMID: 18479788
Full text
Article (Author postprint) (842 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Research group HIV (835)
(ISO format)
DORGHAM, Karim et al. Engineered CCR5 superagonist chemokine as adjuvant in anti-tumor DNA vaccination. In: Vaccine, 2008, vol. 26, n° 26, p. 3252-60. https://archive-ouverte.unige.ch/unige:2086

138 hits



Deposited on : 2009-06-18

Export document
Format :
Citation style :